Navigation Links
Elusys' Anthim(TM) Dramatically Improves Survival of Animals Treated After Active Anthrax Infection
Date:4/22/2008

ith Anthim has the potential to provide 'instant protective immunity' against the anthrax toxin in a bioterrorism emergency. We believe Anthim represents an extremely important medical countermeasure for the treatment of anthrax and should be added to the National Stockpile."

Currently antibiotics represent the only option for the treatment of anthrax infection. Antibiotics may be effective in killing the bacteria, but can still fail to prevent death from the damaging effects of anthrax toxins. In addition, current antibiotics may not be effective at all against antibiotic resistant strains of anthrax.

Anthim Background

Anthim is a high-affinity, humanized and deimmunized monoclonal antibody that targets the protective antigen of B. anthracis and neutralizes the lethal effects of anthrax toxins. It is being developed for prevention and treatment of inhalation anthrax. Anthim has been granted Fast-Track status and Orphan Drug Designation by the FDA and is being developed under the FDA Animal Rule, a regulatory process specifically designed for the development of medical countermeasures to bioterror threats. Elusys has been awarded $32 million from the National Institutes of Health and the Department of Defense for development of Anthim, of which $12 million was awarded in September 2007 from the National Institute of Allergy and Infectious Disease (NIAID), National Institutes of Health, and the Biomedical Advanced Research and Development Authority (BARDA), Department of Health and Human Services for advanced development of Anthim. In April of 2007, Anthim was selected to R&D Directions' list of "100 Great Investigational Drugs."

About Elusys

Based in Pine Brook, New Jersey, venture-backed Elusys has two corporate partnerships with MedImmune and Pfizer for development of its HP Antibodies targeting select infectious diseases. Current venture investors include Essex Woodlands Health Ventures LLC, Invesco Private Capital, Crescendo Ve
'/>"/>

SOURCE Elusys Therapeutics, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. Elusys Therapeutics Appoints Robert Gundel as Vice President of Research
2. Special coating greatly improves solar cell performance
3. Method to deliver molecules within embryonic stem cells improves differentiation
4. Perceptive Informatics Improves Clinical Site Monitoring Access and Flexibility With Portable USB Drive Capability
5. Stimuvax(R) Phase II data highlight three-year survival results for patients with non-small cell lung cancer
6. Survival Data Presented From Phase II Study of Investigational Drug ZD4054 in Hormone-Resistant Prostate Cancer Patients
7. Oncologists Want to See Significant Improvement in Overall Survival Before Adopting Targeted Polytherapy in a First-Line Setting
8. Taxotere(R)-Based Chemotherapy Significantly Improved Overall Survival Compared With Standard Anthracycline-Based Chemotherapy in Early Stage Breast Cancer
9. CHOP-Zevalin(R) Investigational Regimen Produces 95% Complete Remission and 75% Estimated Two Year Progression-Free Survival in Elderly Patients with Diffuse Large B-cell Lymphoma
10. Start Licensing, Inc. Welcomes FDAs Finding of Safety of Food From Cloned Animals
11. Sangamo BioSciences Announces License Agreement For the Use of ZFP Technology For Generation of Transgenic Animals

Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/1/2009)...Newswire/ -- Harvest Technologies Corp. ( www.harv...pany sponsored 60-patient clinical trial conducted...ia using the company,s BMAC System to treat patien... (CLI). Sri Ramachandra Medical Center is a Harvar...ed in Chennai, India and one of the largest privat...
(Date:12/1/2009)... Richard Gephardt Brings Together A-List from New ...r "Best and Brightest Forum on Medical Innovation...Newswire/ -- Several of New Jersey,s most prominen...e and technology gathered today at the Liberty Sci...nnovation in New Jersey, and throughout the United...
(Date:12/1/2009)...RNewswire/ -- Expanding its European reach for bac...ta has appointed Lake Chemicals and Minerals of En...r Birmingham, England. ,, Osprey breeds trilli...tural, waste water, and environmental markets. Its...fields, and clean up industrial and marine spills....
(Date:12/1/2009)...wswire/ -- The Burrill Biotech Select Index manage...tober. The Select,s gain of 4.5 percent mirrored w...rkets with the Dow up 6.5 percent and the NASDAQ u... final two trading days of the month despite inves...opping and Dubai,s reported debt woes. ,, Almos...
Breaking Biology Technology:Harvest Technologies Announces Trial Results in its India Study Using BMAC to Treat Patients With Non-Reconstructable Critical Limb Ischemia 2Harvest Technologies Announces Trial Results in its India Study Using BMAC to Treat Patients With Non-Reconstructable Critical Limb Ischemia 3New Jersey's Best and Brightest Minds Discuss Challenges Facing Medical Innovation, Call for Policies to Preserve U.S. Leadership in Research and Development 2New Jersey's Best and Brightest Minds Discuss Challenges Facing Medical Innovation, Call for Policies to Preserve U.S. Leadership in Research and Development 3New Jersey's Best and Brightest Minds Discuss Challenges Facing Medical Innovation, Call for Policies to Preserve U.S. Leadership in Research and Development 4New Jersey's Best and Brightest Minds Discuss Challenges Facing Medical Innovation, Call for Policies to Preserve U.S. Leadership in Research and Development 5Biotech Gets Back on Track in November 2Biotech Gets Back on Track in November 3Biotech Gets Back on Track in November 4
... Mich., Dec. 18 Stryker Corporation,(NYSE: SYK )...Wednesday,January 23, 2008 at 4:30 p.m., Eastern T...r the quarter and year ended December 31, 2007 and...for the quarter and year,ended December 31, 2007 w.... MacMillan, President and Chief Executive Officer...
..., Ill., Dec. 18 January 1, 2008 will mark the,rit... stop smoking. The New,Year also brings added pres...f the Illinois Smoking Ban., For those resolving ...,technology called low-level laser therapy, is ava...s quickly becoming a very successful aid in,helpin...
... of over 100 RNA-related Inventions a Key Step in ...ndent Company, BOTHELL, Wash., Dec. 18 Nastech,P...STK ) announced today that,it has assigned (i) cer...property and (ii) Nastech,s own intellectual prope...development of RNA-based therapeutics, to its,subs...
Other Biology Technology:Stryker to Host Conference Call on January 23, 2008 2Laser Therapy Gives Smokers Hope for Successful New Year's Resolution 2Nastech Assigns Intellectual Property Related to the Development of RNA-Based Therapeutics to its Subsidiary, MDRNA, Inc. 2Nastech Assigns Intellectual Property Related to the Development of RNA-Based Therapeutics to its Subsidiary, MDRNA, Inc. 3Nastech Assigns Intellectual Property Related to the Development of RNA-Based Therapeutics to its Subsidiary, MDRNA, Inc. 4Nastech Assigns Intellectual Property Related to the Development of RNA-Based Therapeutics to its Subsidiary, MDRNA, Inc. 5
(Date:12/2/2009)... , REDWOOD SHORES, Calif. and PALM HARBOR,...ion Intelligence Corporation ("CIC") (OTC Bulletin...gnature solutions for business process automation ...er** in biometric signature verification and Docub...onal Electronic Document Management (EDM) software...
(Date:12/2/2009)...-walled nanotubescylinders of carbon about a nanom...ial applications such as ultrastrong fibers, elect...age components for fuel cells. Thanks to a new dev...of Standards and Technology (NIST) and five partne...detection and destruction of an aggressive form of...
(Date:12/2/2009)...ntist from the University of Salamanca and another... of predators affects the behaviour of Acanthodac...gev Desert in the Near East. According to the stud...and different prey if they are under pressure from...ted this result, but until now there had been very...
Breaking Biology News(10 mins):CIC Teams with Docubase Systems to Deliver eSignature Enabled Document Management Solutions 2CIC Teams with Docubase Systems to Deliver eSignature Enabled Document Management Solutions 3CIC Teams with Docubase Systems to Deliver eSignature Enabled Document Management Solutions 4Combining nanotubes and antibodies for breast cancer 'search and destroy' missions 2Lizards change their diet to avoid predators 2Parents Worry About Their Kids Safety on the Internet 62016 1Parents Worry About Their Kids Safety on the Internet 62016 2Researchers establish common seasonal pattern among bacterial communities in Arctic rivers 10885 1Researchers establish common seasonal pattern among bacterial communities in Arctic rivers 10885 2Jamba Juice and Think Wow Toys Bring the Smoothie Experience Home With Debut of Jamba Branded Toy Blender 62012 1Jamba Juice and Think Wow Toys Bring the Smoothie Experience Home With Debut of Jamba Branded Toy Blender 62012 2Jamba Juice and Think Wow Toys Bring the Smoothie Experience Home With Debut of Jamba Branded Toy Blender 62012 3
...ven the tiny, mild-mannered fruit fly can be a lit...ce bit of rotten fruit to fight over. And, like pe... , Researchers in the North Carolina Sate Univers... genes that affect aggression in the fruit fly Dro...hat could contribute to abnormal aggression in hum...
... group of scientists led by the New York-based Wil...ia,s windswept Gobi Desert recently fitted high-te...t saiga antelope in an effort to help protect one ...rge mammals. , Standing just under two feet at the...triking feature of the saiga is its large nose, or...
...n enzyme found naturally in the brain snips apart ...laque that is one of the hallmarks of Alzheimer,s ...eir findings in mice suggest that the protein, cal...ive mechanism that may fail in some forms of AD. A...o enhance CatB activity could break down amyloid d...
Other Biology News:Fruit fly aggression studies have relevance to humans, animals 2Fruit fly aggression studies have relevance to humans, animals 3Asia's odd-ball antelope gets collared 2Enzyme shreds Alzheimer's protein 2
Anti-Feline Rhinotracheitis Virus Monoclonal Antibody, Unconjugated from ViroStat Inc.
Rabbit Anti-NFkB p105 / p50, phospho (Ser529) Antibody, Unconjugated from Raybiotech, Inc.
Rat Anti-Mouse ABCA1 Monoclonal Antibody, Unconjugated, Clone 5A1-1422.11 from ABR-Affinity BioReagents
Mouse Anti-Human Actopaxin, phospho (Ser8) Monoclonal Antibody, Unconjugated, Clone J160-366 from BD Biosciences Pharmingen
Biology Products: